Drugs / fecal microbial transplantation
fecal microbial transplantation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06022406 | Jul 2024 → Aug 2025 | HIV infectious disease | Jean-Pierre Routy | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fecal microbial transplantation | “A promising intervention is the use of fecal microbial transplantation (FMT), which consist of delivering stool microbiota from a donor by upper-endoscopy in the stomach or colonoscopy.” NCT06022406 ↗ |
| Known as | fecal microbiota transplantation | “Fecal microbiota transplantation (FMT) from healthy volunteer is a promising therapy to counteract dysbiosis, protect from gut barrier damage, and lower systemic immune activation.” PMID 41390455 ↗ Dec 2025 |
| Known as | FMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06022406 ↗ |
| Modality | Other / unclassified | “Fecal microbiota transplantation (FMT) from healthy volunteer is a promising therapy to counteract dysbiosis, protect from gut barrier damage, and lower systemic immune activation.” PMID 41390455 ↗ Dec 2025 |
| Route | Oral | “More recently, oral delivery of encapsulated stool preparation was shown to lead to a more stable engraftment of the donor's microbiota.” NCT06022406 ↗ |